Literature DB >> 7238562

Influence of phenobarbital treatment on cimetidine kinetics.

A Somogyi, S Thielscher, R Gugler.   

Abstract

The pharmacokinetics of orally administered cimetidine was studied in 8 healthy subjects before and after 3 weeks of treatment with phenobarbital 100 mg daily, and in a separate study 4 subjects received cimetidine intravenously before and after the administration of phenobarbital. There was no change in the volume of distribution, but total plasma clearance was increased by a mean of 18%, mainly due to a 37% increase of nonrenal clearance. Renal clearance and half-life were not significantly altered. The area under the plasma concentration-time curve after oral administration was significantly (P less than 0.05) reduced by a mean of 15% after phenobarbital treatment. The amount of cimetidine excreted in urine and its sulphoxide metabolite were significantly (P less than 0.05) reduced, on average by 34% and 26%, respectively by phenobarbital treatment. The data indicate that an apparent 20% reduction in the absorption of cimetidine was due to induction of gastrointestinal metabolism of cimetidine, with some contribution also from hepatic metabolism. Reduced absorption per se could not be totally excluded. Although the magnitude of the change was small, the finding of an 11% decrease in the time to achieve an effective plasma level of cimetidine after phenobarbital treatment may contribute to the ineffectiveness of cimetidine in certain patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7238562     DOI: 10.1007/bf00544584

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

3.  Bioavailability and pharmacokinetics of cimetidine.

Authors:  A Grahnén; C von Bahr; B Lindström; A Rosén
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

4.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

5.  Bioavailability of cimetidine in man.

Authors:  S S Walkenstein; J W Dubb; W C Randolph; W J Westlake; R M Stote; A P Intoccia
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

6.  Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.

Authors:  A Somogyi; H G Rohner; R Gugler
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

7.  Blood level of cimetidine in relation to age.

Authors:  A Redolfi; E Borgogelli; E Lodola
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of anticonvulsants.

Authors:  E F Hvidberg; M Dam
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Relationship between cimetidine plasma levels and gastric acidity in acutely ill patients.

Authors:  I A Cohen; J K Siepler; R Nation; C T Bombeck; L M Nyhus
Journal:  Am J Hosp Pharm       Date:  1980-03

10.  Cimetidine: interaction with oral anticoagulants in man.

Authors:  M J Serlin; R G Sibeon; S Mossman; A M Breckenridge; J R Williams; J L Atwood; J M Willoughby
Journal:  Lancet       Date:  1979-08-18       Impact factor: 79.321

View more
  11 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 4.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Cimetidine pharmacokinetics and dosage requirements in children.

Authors:  A Somogyi; M Becker; R Gugler
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 8.  Drug treatment of epilepsy: a review.

Authors:  D Rosenbloom; A R Upton
Journal:  Can Med Assoc J       Date:  1983-02-01       Impact factor: 8.262

9.  Altered disposition and availability of cimetidine in liver cirrhotic patients.

Authors:  R Gugler; B Müller-Liebenau; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 10.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.